This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00019-08v1 52/6/2149    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Stephan, B. Articles by Silley, P. PubMed PubMed Citation Articles by Stephan, B. Articles by Silley, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 2149-2155, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.00019-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Activity of Pradofloxacin against Porphyromonas and Prevotella spp. Implicated in Periodontal Disease in Dogs: Susceptibility Test Data from a European Multicenter Study

Bayer HealthCare AG, Animal Health Division, Leverkusen D-51368, Germany,¹ Don Whitley Scientific Ltd., Shipley, West Yorkshire BD17 7SE, United Kingdom,² MB Consult Limited, Lymington SO41 3TQ, United Kingdom,³ Department of Biomedical Sciences, University of Bradford, Bradford, United Kingdom⁴

Received 5 January 2008/ Returned for modification 26 March 2008/ Accepted 5 April 2008

Collaborating veterinarians from five European countries collected subgingival bacterial samples from dogs exhibiting clinical periodontal disease. Sterile endodontic paper points were used for collection of the samples, which were transported to a central laboratory for susceptibility testing. Anaerobic bacteria were isolated and Porphyromonas and Prevotella isolates identified to the species level; susceptibility to pradofloxacin and metronidazole was determined using the CLSI agar dilution methodology. A total of 630 isolates, 310 of Porphyromonas spp. and 320 of Prevotella spp., were isolated. Pradofloxacin MIC data for all isolates were in the range of 0.016 to 1 µg/ml, the overall MIC₅₀ was 0.062, and the overall MIC₉₀ was 0.25 µg/ml. There were no differences in activity against Porphyromonas and Prevotella isolates or in the pradofloxacin susceptibility distributions from the different European countries. All isolates were within the wild-type distribution and were fully susceptible to pradofloxacin. Metronidazole was also highly active against these strains: 316 of 320 Prevotella strains (98.8%) and 309 of 310 Porphyromonas strains (99.7%) were susceptible (MICs of 8 µg/ml). However, three Prevotella strains had intermediate metronidazole susceptibility (MICs of 16 µg/ml), while one Prevotella and one Porphyromonas strain were metronidazole resistant (MICs of 128 and 256 µg/ml, respectively). Pradofloxacin, a novel broad-spectrum fluoroquinolone, demonstrates a high degree of antianaerobic activity against strains isolated from clinical cases of periodontal disease and shows activity against metronidazole-resistant isolates. The broad-spectrum activity of pradofloxacin makes it a suitable candidate for the treatment of periodontal disease in dogs.

Published ahead of print on 14 April 2008.